Human hepatocyte carcinogenesis (review)

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1133-1138

  Shiraha, Hidenori ^a   Yamamoto, Kazuhide ^a   Namba, Masayoshi ^b  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Niimi University   (Japan)

Author keywords

Gene alteration; Hepatocarcinogenesis; Tumor suppressor genes

Indexed keywords

B RAF KINASE; CORE PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN B RECEPTOR; SONIC HEDGEHOG PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR; WNT PROTEIN;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CELL IMMORTALIZATION; CELL SURVIVAL; ENZYME ACTIVITY; GENE MUTATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IONIZING RADIATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE K RAS; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; TELOMERE; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; GENES, NEOPLASM; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL;

EID: 84874598132     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1829     Document Type: Review

References (87)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576, 2007.
2. Garcia M, Jernal A, Ward EM, et al: Global Cancer Facts & Figures 2007. Journal 2007.
3. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 1999.
4. Bosch FX, Ribes J and Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 19:271-285, 1999.
5. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999.
6. Nakakura EK and Choti MA: Management of hepatocellular carcinoma. Oncology (Williston Park) 14:1085-1102, 2000.
7. El-Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752-1763, 2008.
8. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008.
9. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708, 1989.
10. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991.
11. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991.
12. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR and Ozturk M: Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87:1973-1977, 1990.
13. Bourdon JC: p53 and its isoforms in cancer. Br J Cancer 97:277-282, 2007.
14. Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283, 2007.
15. Ozturk M: Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 19:235-242, 1999.
16. Tannapfel A, Busse C, Weinans L, et al: INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 20:7104-7109, 2001.
17. Bressac B, Kew M, Wands J and Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431, 1991.
18. Buendia MA: Genetics of hepatocellular carcinoma. Semin Cancer Biol 10:185-200, 2000.
19. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K and Maeda S: p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 54:231-235, 1994.
20. Ueda H, Ullrich SJ, Gangemi JD, et al: Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9:41-47, 1995.
21. Pantoja E, Beecher TS and Cross VF: Cutaneous lymphangiosarcoma of Stewart-Treves. Cutis 17:883-886, 1976.
22. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000.
23. Higashitsuji H, Itoh K, Nagao T, et al: Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 6:96-99, 2000.
24. Hsia CC, Di Bisceglie AM, Kleiner DE Jr, Farshid M and Tabor E: RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. J Med Virol 44:67-73, 1994.
25. Azechi H, Nishida N, Fukuda Y, et al: Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 60:346-354, 2001.
26. Liew CT, Li HM, Lo KW, et al: High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 18:789-795, 1999.
27. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K and Asakura H: p16 (INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116:394-400, 1999.
28. Li DM and Sun H: PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95:15406-15411, 1998.
29. Hu TH, Huang CC, Lin PR, et al: Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97:1929-1940, 2003.
30. Li QL, Ito K, Sakakura C, et al: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113-124, 2002.
31. Mori T, Nomoto S, Koshikawa K, et al: Decreased expression and frequent allelic inactivation of the RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int 25:380-388, 2005.
32. Miyagawa K, Sakakura C, Nakashima S, et al: Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res 26:3633-3643, 2006.
33. Li X, Zhang Y, Qiao T, et al: RUNX3 inhibits growth of HCC cells and HCC xenografts in mice in combination with adriamycin. Cancer Biol Ther 7:669-676, 2008.
34. Nakanishi Y, Shiraha H, Nishina S, et al: Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer 11:3, 2011.
35. Tanaka S, Shiraha H, Nakanishi Y, et al: Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer 131:2537-2546, 2012.
36. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP and Thorgeirsson SS: Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 54:281-285, 1994.
37. Kawai H, Suda T, Aoyagi Y, et al: Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 31:1246-1250, 2000.
38. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR and Goel A: Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47:908-918, 2008.
39. Yang B, Guo M, Herman JG and Clark DP: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163:1101-1107, 2003.
40. Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ and Guan XY: Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95:2346-2352, 2002.
41. Shachaf CM, Kopelman AM, Arvanitis C, et al: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431:1112-1117, 2004.
42. Tada M, Omata M and Ohto M: Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 50:1121-1124, 1990.
43. Challen C, Guo K, Collier JD, Cavanagh D and Bassendine MF: Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J Hepatol 14:342-346, 1992.
44. Stork P, Loda M, Bosari S, Wiley B, Poppenhusen K and Wolfe H: Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. Oncogene 6:857-862, 1991.
45. Weihrauch M, Benick M, Lehner G, et al: High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride. Int Arch Occup Environ Health 74:405-410, 2001.
46. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002.
47. de La Coste A, Romagnolo B, Billuart P, et al: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95:8847-8851, 1998.
48. Csepregi A, Rocken C, Hoffmann J, et al: APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 134:579-589, 2008.
49. Legoix P, Bluteau O, Bayer J, et al: Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 18:4044-4046, 1999.
50. Huang S, He J, Zhang X, et al: Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 27:1334-1340, 2006.
51. Nusslein-Volhard C and Wieschaus E: Mutations affecting segment number and polarity in Drosophila. Nature 287:795-801, 1980.
52. Nybakken K and Perrimon N: Hedgehog signal transduction: recent findings. Curr Opin Genet Dev 12:503-511, 2002.
53. Cohen MM Jr and Shiota K: Teratogenesis of holoprosencephaly. Am J Med Genet 109:1-15, 2002.
54. Mullor JL, Sanchez P and Ruiz i Altaba A: Pathways and consequences: Hedgehog signaling in human disease. Trends Cell Biol 12:562-569, 2002.
55. Stecca B, Mas C and Ruiz i Altaba A: Interference with HH-GLI signaling inhibits prostate cancer. Trends Mol Med 11:199-203, 2005.
56. Patil MA, Zhang J, Ho C, Cheung ST, Fan ST and Chen X: Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther 5:111-117, 2006.
57. Schaff Z, Hsia CC, Sarosi I and Tabor E: Overexpression of transforming growth factor-alpha in hepatocellular carcinoma and focal nodular hyperplasia from European patients. Hum Pathol 25:644-651, 1994.
58. Hsia CC, Axiotis CA, Di Bisceglie AM and Tabor E: Transforming growth factor-alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver. Cancer 70:1049-1056, 1992.
59. Yamada T, De Souza AT, Finkelstein S and Jirtle RL: Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci USA 94:10351-10355, 1997.
60. De Souza AT, Hankins GR, Washington MK, Orton TC and Jirtle RL: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11:447-449, 1995.
61. Dennis PA and Rifkin DB: Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 88:580-584, 1991.
62. Kawate S, Takenoshita S, Ohwada S, et al: Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol 14:127-131, 1999.
63. Harley CB: Telomere loss: mitotic clock or genetic time bomb? Mutat Res 256:271-282, 1991.
64. Harley CB, Futcher AB and Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345:458-460, 1990.
65. Counter CM, Avilion AA, Le Feuvre CE, et al: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921-1929, 1992.
66. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994.
67. Counter CM, Hirte HW, Bacchetti S and Harley CB: Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91:2900-2904, 1994.
68. Hiyama E, Gollahon L, Kataoka T, et al: Telomerase activity in human breast tumors. J Natl Cancer Inst 88:116-122, 1996.
69. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791, 1997.
70. Kojima H, Yokosuka O, Imazeki F, Saisho H and Omata M: Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 112:493-500, 1997.
71. Nagao K, Tomimatsu M, Endo H, Hisatomi H and Hikiji K: Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol 34:83-87, 1999.
72. Namba M, Mihara K and Fushimi K: Immortalization of human cells and its mechanisms. Crit Rev Oncog 7:19-31, 1996.
73. McCormick JJ and Maher VM: Towards an understanding of the malignant transformation of diploid human fibroblasts. Mutat Res 199:273-291, 1988.
74. Linder S and Marshall H: Immortalization of primary cells by DNA tumor viruses. Exp Cell Res 191:1-7, 1990.
75. Schippers IJ, Moshage H, Roelofsen H, et al: Immortalized human hepatocytes as a tool for the study of hepatocytic (de-) differentiation. Cell Biol Toxicol 13:375-386, 1997.
76. Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni JF Jr and Goedert JJ: Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 279:292-295, 1998.
77. Faller DV, Kourembanas S, Ginsberg D, et al: Immortalization of human endothelial cells by murine sarcoma viruses, without morphologic transformation. J Cell Physiol 134:47-56, 1988.
78. Morgan TL, Yang DJ, Fry DG, et al: Characteristics of an infinite life span diploid human fibroblast cell strain and a near-diploid strain arising from a clone of cells expressing a transfected v-myc oncogene. Exp Cell Res 197:125-136, 1991.
79. Moriya K, Nakagawa K, Santa T, et al: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61:4365-4370, 2001.
80. Ray RB, Meyer K and Ray R: Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 271:197-204, 2000.
81. Moriya K, Fujie H, Shintani Y, et al: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067, 1998.
82. Pfeifer AM, Cole KE, Smoot DT, et al: Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci USA 90:5123-5127, 1993.
83. Fukaya K, Asahi S, Nagamori S, et al: Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT. In Vitro Cell Dev Biol Anim 37:266-269, 2001.
84. Schaff Z, Kovalszky I, Nagy P, Zalatnai A, Jeney A and Lapis K: Human and experimental hepatocarcinogenesis. Scand J Gastroenterol (Suppl) 228:90-97, 1998.
85. Buchmann A, Ziegler S, Wolf A, Robertson LW, Durham SK and Schwarz M: Effects of polychlorinated biphenyls in rat liver: correlation between primary subcellular effects and promoting activity. Toxicol Appl Pharmacol 111:454-468, 1991.
86. Jaworski M, Hailfinger S, Buchmann A, et al: Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogenesis 26:1829-1834, 2005.
87. Unger C, Buchmann A, Bunemann CL, Kress S and Schwarz M: Wild-type function of the p53 tumor suppressor protein is not required for apoptosis of mouse hepatoma cells. Cell Death Differ 5:87-95, 1998.